drugset

drugset / Trial / NCT06900010

A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease

NCT06900010 ↗

Phase 2 Recruiting 30 enrolled Shandong First Medical University

NaSingle-groupOpen-labelTreatment

Summary

to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease

Timeline

Start: 2025-04-22
Primary completion: 2027-01-01
Completion: 2028-01-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CM336	Monoclonal antibody	—	Subcutaneous

Indications